<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        18-5015-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOACT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        59.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIOS CINFA SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What this medicine is<br />The active substance in your tablets is levofloxacin. This belongs to a group of medicines known as fluoroquinolone antibiotics, which kill bacteria.<br />What this medicine does<br />Levoact tablets are used to treat infections caused by bacteria that are sensitive to levofloxacin. Your doctor will have decided if your infection can be treated with this medicine. Levoact can be used to treat infections of the:<br />- Sinuses<br />- Lungs, in people with long-term breathing problems or pneumonia<br />- Urinary tract, including your kidneys or bladder<br />- Prostate gland, where you have a long lasting infection<br />- Skin and underneath the skin, including muscles. This is sometimes called &lsquo;soft tissue&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Levoact tablets<br />&bull; if you are allergic (hypersensitive) to Levofloxacin or to other active substances that belong to the same group of antibiotics (i.e. quinolones) or to any of the other ingredients of the medicine.<br />&bull; if you suffer from epilepsy. Otherwise, your risk of getting &ldquo;fits&rdquo; (convulsions) is increased.<br />&bull; if you had ever had tendon problems (e.g. tendonitis) relating to treatment with an active substance that belongs to the same class of antibiotics (i.e. fluoroquinolones).<br />&bull; if you are or planning to become pregnant or if you are breast feeding.<br />&bull; if the tablets have been prescribed to children or growing teenagers. They could harm the cartilage of their growing bones. The tablets are only intended for adults.<br />Tell your doctor if you have had any problems with taking medicines in the past.<br />Take special care with Levoact tablets<br />&bull; if you have experienced &ldquo;fits&rdquo; or brain damage in the past (such as stroke or severe brain injury). Make sure your doctor knows about your medical history, so he can give you appropriate advice.<br />&bull; when you are exposed to sunlight or UV light. Do not stay out in strong sunlight for unnecessarily long periods and do not use a sun-lamp or solarium. Your skin may become more sensitive to light whilst using this medicine (may cause sunburn &ndash; like reactions).<br />&bull; if you get pain or inflammation in your tendons, particularly if you are elderly or taking any medicines known as the corticosteroids (cortisone or similar medicines used as anti&ndash;inflammatories in many disorders such as asthma, allergic conditions/reactions and arthritis). If you experience any tendon complaints whilst or shortly after taking the tablets you should seek medical advice immediately and rest the affected limb to avoid tendon damage. Do not take the next dose of Levoact unless your doctor tells you to.<br />&bull; if you have severe, persistent and/or bloody diarrhoea during or after treatment with the tablets. This may be a sign of serious bowel inflammation (pseudomembranous colitis) which can occur following treatment with antibiotics. Tell your doctor immediately. It may be necessary to stop treatment and start specific therapy.<br />&bull; if you have a family history of or have an actual defect in the liver enzyme called glucose-6-phosphate dehydrogenase (G6PD) (a rare hereditary disease). Patients with G6PD deficiency may be prone to destruction of red blood cells (haemolysis) when treated with quinolone antibacterial agents.<br />&bull; if you suffer from kidney problems. Patients with reduced kidney activity (renal insufficiency) may need lower doses than patients with normal kidney activity.<br />&bull; if you are taking any medicines which thin the blood (known as anti&ndash;coagulants e.g. warfarin).<br />&bull; if you have ever had mental health problems. Tell your doctor immediately if your opinion and thoughts change (a psychotic reaction).<br />&bull; if you have ever had symptoms due to nerve damage such as movement or sensory problems in hand and feet, that are more severe at night..<br />&bull; if you have ever had heart problems.<br />&bull; if you are diabetic and taking medicines by mouth that lowers blood glucose levels.<br />&bull; if you have ever had liver problems. You should stop treatment and contact your doctor immediately if symptoms of liver disease develop such as reduced appetite, yellowing of the skin or whites of the eyes (jaundice), dark urine, itching or gastrointestinal disturbances.<br />&bull; if you have allergic reactions to the medicine. In that case, you should stop treatment immediately and contact your doctor or an emergency doctor.<br />Heart problems<br />Caution should be taken when using this kind of medicine, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have a very slow heart rhythm (called &#39;bradycardia&#39;), have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes (see section Taking other medicines)<br />If your eyesight becomes impaired or if your eyes seem to be otherwise affected, consult an eye specialist immediately.<br />Taking other medicines<br />You must tell your doctor if you are taking other medicines that can alter your heart rhythm: medicines that belong to the group of anti-arrhythmics ) e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotatol, dofetilide, ibutilide), tricyclic antidepressants, some antimicrobials (that belong to the group of macrolides) some antipsychotics.<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines you buy without a prescription, including herbal medicines.<br />Some medicines can interfere with your treatment or alter blood levels of those medicines you are currently taking, so make sure to check with your doctor or pharmacist before taking any other medications whether prescribed by a doctor or bought by you over the counter. In particular tell your doctor if you are taking any of the following:<br />&bull; iron salts (used to treat anaemia), magnesium- or aluminium &ndash; containing antacids (medicines against heartburn and stomach pain) or medicines containing these salts. These drugs can reduce the absorption and efficacy of Levoact tablets and as such they should be taken at least 2 hours before or after Levoact tablets.<br />&bull; sucralfate (used to protect the stomach wall). It may affect the absorption and reduce the efficacy of Levoact tablets. It is best to take sucralfate 2 hours after Levoact tablets.<br />&bull; Vitamin K antagonists such as warfarin (used to prevent blood clots). In combination with Levoact tablets may lead to an increase in bleeding.<br />&bull; theophylline (used to treat asthma). The risk of getting &ldquo;fits&rdquo; may be increased.<br />&bull; probenecid (used to prevent gout) or cimetidine (used to treat ulcers) reduce your kidneys ability to get rid of levofloxacin.<br />&bull; ciclosporin (e.g. used to treat psoriasis, dermatitis, rheumatism). The effect of this medicine may be prolonged if used in combination with Levoact tablets.<br />&bull; corticosteroids, sometimes called steroids &ndash; used for inflammation. You may be more likely to have inflammation and/or breakage of your tendons.<br />&bull; non-steroidal anti-inflammatory drugs (NSAIDS) &ndash; used for pain and inflammation such as aspirin, ibuprofen, fenbufen, ketoprofen and indomethacin. You are more likely to have a fit (seizure) if taken with Levoact tablets.<br />Taking Levoact tablets with food and drink<br />Levoact tablets may be taken during meals or at any time between meals. Swallow the tablets with a glass of water.<br />Pregnancy and Breast-feeding<br />Do not take Levoact tablets if you are pregnant or breast feeding a baby. It could harm your baby.<br />Driving and using machines<br />Some side &ndash; effects like dizziness, drowsiness and visual disturbances may impair your ability to concentrate and react. Do not drive, operate dangerous machinery or have similar activities if you feel that your ability to concentrate and react is impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Levoact exactly as your doctor has told you.<br />You should check with your doctor or your pharmacist if you are not sure.<br />The duration of the treatment depends on the type and severity of your infection.<br />Your doctor will tell you how many tablets to take, at what time and for how long.<br />Most people need a dose of one or two tablets per day. Patients with reduced kidney activity may need lower doses.<br />Taking this medicine<br />&bull; Take this medicine by mouth<br />&bull; Swallow the tablets whole with a glass of water<br />&bull; The tablets may be taken during meals or at any time between meals<br />Protect your skin from sunlight<br />Keep out of direct sunlight while taking this medicine. This is because your skin will become much more sensitive to the sun and may burn, tingle or severely blister if you do not take the following precautions:<br />&bull; Make sure you use high factor sun creams<br />&bull; Always wear a hat and clothes which cover your arm and legs.<br />&bull; Avoid sun beds.<br />If you are already taking iron tablets, antacids or sulcralfate<br />&bull; Do not take this medicine at the same time as Levoact film-coated tablets. Take your dose of these<br />medicines at least 2 hours before or after Levoact film-coated tablets.<br />How much to take<br />&bull; Your doctor will decide on how many Levoact film-coated tablets you should take.<br />&bull; The dose will depend on the type of infection you have and where the infection is in your body.<br />&bull; The length of your treatment will depend on how serious your infection is<br />&bull; If you feel the effect of your medicine is too weak or strong, do not change the dose yourself, but ask your doctor.<br />Adults and the elderly<br />Infections of sinuses<br />One tablet of Levoact 500 mg, once each day.<br />Infection of the lungs, in people with long term breathing problems<br />&frac12; tablet or one tablet Levoact 500 mg , once each day<br />Pneumonia<br />One tablet of Levoact 500mg , once or twice each day.<br />Infection of the urinary track, including your kidneys or bladder<br />&frac12; tablet of Levoact 500 mg ,each day<br />Infection of the prostate gland, where you have a long lasting infection<br />One tablet of Levoact 500 mg, once each day.<br />Infection of the skin and underneath the skin, including muscles<br />&frac12; tablet or one tablet Levoact 500 mg , once or twice each day<br />Adults with kidney problems<br />Your doctor may need to give you a lower dose<br />Children and teenagers<br />The medicine must not be given to children and teenagers.<br />If you take more Levoact tablets than you should<br />If you accidentally take one tablet too many, nothing is likely to happen. If you accidentally take several tablets too many, contact your doctor or get other medical advice. If possible, take your tablets or the box with you to show the doctor. The signs of an overdose include symptoms such as confusion, dizziness, impairment of consciousness, (convulsive) fits and heart disorder, possibly leading to abnormal heart rhythm.<br />If you forget to take Levoact tablets<br />If you forget to take a dose, take it as soon as you remember, unless it is nearly time for you to take your next dose. Then go on as before. Do not take a double dose to make up for a missed dose.<br />If you stop taking Levoact tablets<br />It is important to finish your course of tablets as prescribed by your doctor. Do not stop, even if you begin to feel better before you have finished them all. If you stop the tablets too soon your condition may get worse. If you feel you have to stop of a side effect, tell a doctor immediately to get advice before taking the next dose.<br />If you have any further questions on the use of this product, ask your doctor or your pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all other medicines Levoact can cause side effects although not everybody gets them. The side effects in this section are given with an estimation of the frequency with which they may occur. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.<br />Severe allergic reactions can occur very rarely. These can happen after the first dose or even after treatment has stopped. If you get any of these side effects while having your medicine, stop having Levoact immediately and tell your doctor or go to the nearest hospital casualty department. Signs of an allergic reaction are:<br />fast heart rate, low blood pressure, fever, breathing problems, shock,<br />swelling of the face, tongue and throat, skin reactions such as swelling and redness, blood problems, ulcers in the mouth, eyes, gut and genital organs,<br />severe liver problems can develop in some people. Signs of liver problems include yellow skin, dark urine, stomach tenderness and loss of appetite.<br />unaccountable muscle pain, muscle weakness muscle cramps.<br />Bloody diarrhoea, fever, and mild to moderate stomach cramps (symptoms of pseudomembranous colitis).<br />&bull; tendon rupture (e.g.: Achilles tendon), which may occur within 48 hours after starting treatment and may be bilateral, muscular weakness, which may be of special importance in patients with myasthenia gravis (a rare disease of the nervous system)<br />Levofloxacin may cause a reduction in the number of white blood cells and your resistance to infection may be decreased. If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis). It is important to inform your doctor about your medicine.<br />Other side effects include<br />Common affects 1 to 10 users in 100<br />&bull; Nausea, diarrhoea<br />&bull; Increase in blood levels of liver enzymes<br />Uncommon affects 1 to 10 users in 1000<br />&bull; Itching and rash<br />&bull; Loss of appetite, stomach upset (dyspepsia), vomiting or pain in the abdominal region<br />&bull; Headache, dizziness, drowsiness, sleeping problems<br />&bull; Increase or decrease in the number of white blood cells<br />&bull; General weakness. Any antibacterial treatment that kills certain germs may lead to a disturbance of the micro&ndash;organisms (bacteria / fungi) that are normally found in humans. Consequently, the number of other bacteria or fungi may increase, which in rare cases requires treatment<br />Rare affects 1 to 10 users in 10,000<br />&bull; General allergic reactions (anaphylactic / anaphylactoid reactions) (which may sometimes occur even after the first dose and which may develop fast within minutes or hours of intake) with symptoms such as eheals (urticaria), cramping of the bronchi and possibly severe breathing problems, as well as in very rare cases swelling of the skin and mucous membranes (e.g. in the face and throat)<br />&bull; Feeling like tingling, e.g. in the hands (paraesthesia), trembling, &ldquo;fits&rdquo; (convulsions) and confusion<br />&bull; Anxiety, depression, psychotic reactions, restlessness (agitation)<br />&bull; Abnormally rapid beating of the heart, abnormally low blood pressure<br />&bull; Tendon pain and inflammation (tendonitis), joint pain or muscle pain<br />&bull; Decrease in the number of blood platelets leading to tendency to bruise and bleed easily<br />Very rare affects less than 1 user in 10,000<br />&bull; Sudden drop in blood pressure or collapse (shock), mild skin reactions, increased sensitivity of the skin to sun and ultraviolet light<br />&bull; Decrease in blood sugar to a too low level (hypoglycaemia) which may be of special importance in patients treated for diabetes, attacks of porphyria in patients with porphyria (a very rare metabolic disease)<br />&bull; Vision and hearing disorders, disturbances of taste and smell, numbness, disorders of movement, including walking difficulties.<br />&bull; Hallucinations, psychotic reactions with risk of suicidal thoughts or actions.<br />&bull; Circulatory collapse (anaphylactic like shock).<br />&bull; Severe decrease in the number of white blood cells (agranulocytosis) leading to symptoms such as recurrence or persistence of fever, sore throat and feeling more ill again<br />&bull; Inflammation of the liver; disturbances of kidney function and occasional kidney failure due to allergic kidney reactions (interstitial nephritis).<br />&bull; Fever, allergic inflammation of small blood vessels or allergic lung reactions.<br />Not known frequency cannot be estimated from the available data.<br />&bull; Severe blistering reactions of the skin and mucous membranes (Steven&rsquo;s Johnson syndrome), toxic epidermal necrolysis (Lyells&rsquo; syndrome) and erythema exsudativum multiforme.<br />&bull; Decrease in red blood cells (anaemia) due to blood cell damage, decrease in the number of all types of blood cells.<br />Heart problems<br />Not known: Abnormal fast heart rhythm, life-threatening irregular heart rhythm &#39;alteration of the heart rhythm (called &#39;prolongation of QT interval&#39;, seen on ECG, electrical activity of the heart.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use this medicine after the expiry date which is shown on the packaging. The expiry date refers to the last day of the month.<br />Do not store at a temperature above 30&ordm;C.<br />Keep the blister in the outer carton in order to protect from light.<br />Medicines should not be disposed of via wastewater of household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each tablet of Levoact 500 mg tablets contains 500 mg of levofloxacin.<br />The other ingredients are:<br />Tablet core: hydroxypropyl methylcellulose, crospovidone, microcrystalline cellulose, colloidal anhydrous silica, pregelatinized corn starch and sodium stearyl fumarate.<br />Film coating: Opadry Y-1-7000 and red iron oxide (E-172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Levoact 500 mg film-coated tablets are biconvex pink color film coated oblong tablets,
scored and with “L” engraved on one side. The tablet can be divided into equal halves.
Each pack contains 10 tablets (one blister of 10 tablets).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Laboratorios Cinfa, S.A.<br />Olaz-Chipi, 10 - Pol&iacute;gono Industrial Areta.<br />31620-Huarte-Pamplona (Navarra) &ndash; Spain<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما مكونات هذا الدواء </strong></p><p dir="RTL">المادة الفعالة في هذه الأقراص هي ليفوفلوكساسين. ينتمي هذا العقار إلى مجموعة من أدوية المضادات الحيوية تُعرف باسم الفلوروكينولون، التي تقتل البكتيريا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>فيما يستخدم هذا الدواء </strong></p><p dir="RTL">تُستخدم أقراص ليفوأكت لعلاج العدوى التي تسببها البكتيريا ذات الحساسية لمادة الليفوفلوكساسين. سيقرر طبيبك ما إذا كان من الممكن استخدام هذا الدواء لعلاج العدوى لديك. يمكن استخدام ليفوأكت لعلاج عدوى:</p><p dir="RTL">- الجيوب الأنفية</p><p dir="RTL">- الرئتين، في الأشخاص الذين يعانون مشكلات طويلة الأمد في التنفس أو من التهاب رئوي</p><p dir="RTL">- الجهاز البولي، ويشمل الكليتين أو المثانة البولية</p><p dir="RTL">- غدة البروستاتا، حيث تكون مصاباً بعدوى لمدة طويلة</p><p dir="RTL">- الجلد وما تحت الجلد، بما في ذلك العضلات. وتُعرف أحياناً باسم &quot;الأنسجة الرخوة&quot;.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تُستخدم أقراص ليفوأكت في الحالات التالية </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بحساسية (حساسية مفرطة) لمادة ليفوفلوكساسين أو أي من المواد الفعاله الأخرى التي تنتمي إلى نفس مجموعة المضادات الحيوية (أي الكينولونات) أو أي من مكونات الدواء الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني مرض الصرع. خلاف ذلك، يزداد خطر الإصابة &quot;بنوبات صرع&quot; (تشنجات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت مُسبقاً بمشكلات في الأوتار (مثل التهاب الأوتار) نتيجة للعلاج بمادة فعالة تنتمي إلى نفس الفئة من المضادات الحيوية (أي الفلوروكينولونات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تخططين لحدوث حمل أو كنت في فترة الإرضاع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وُصفت هذه الأقراص للأطفال أو البالغين في مرحلة النمو. فربما تتسبب في إلحاق الضرر بغضاريف عظامهم النامية. <strong>هذه الأقراص صالحة للاستخدام من قبل البالغين فقط</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت قد عانيت أي مشكلة مع تناول هذا الدواء فيما مضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخي العناية الخاصة عند تناول أقراض ليفوأكت </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت من قبل &quot;بنوبات صرع&quot; أو بتلف في خلايا المخ في الماضي (مثل سكتة دماغية أو إصابة حادة في المخ)، تأكد من إطلاع طبيبك على تاريخك الطبي، حتى يمكنه إعطاؤك النصيحة المناسبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تتعرض لأشعة الشمس أو الأشعة فوق البنفسجية. تجنب التعرض لأشعة الشمس القوية لفترات زمنية طويلة دون الحاجة إلى ذلك وتجنب استخدام مصباح شمسي أو غرفة شمسية. قد تُصبح بشرتك أكثر حساسية للضوء خلال فترة العلاج بهذا الدواء (قد يُسبب تفاعلات حساسية شبيهة بحروق الشمس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بألم أو التهاب في أوتارك، وخاصة إذا كنت متقدماً في العمر أو تتناول أي أدوية تُعرف باسم الكورتيكوستيرويدات (الكورتيزون أو الأدوية المشابهة التي تُستخدم كمضادات للالتهاب في علاج العديد من الاضطرابات مثل الربو وأمراض/تفاعلات الحساسية والتهاب المفاصل. إذا كان لديك أي شكوى من الأوتار خلال تناول الأقراص أو بعد تناولها بفترة قصيرة، يجب عليك الحصول على استشارة طبية على الفور وعدم إجهاد الطرف المُصاب لتجنب إلحاق أي ضرر بالأوتار. لا تتناول الجرعة التالية من دواء ليفوأكت إلا إذا أخبرك الطبيب بذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني إسهالاً حاداً أو دائماً و/أو مصحوباً بدم خلال فترة العلاج بأقراص ليفوأكت أو بعدها. فربما يكون ذلك دليلاً على الإصابة بالتهاب حاد في الأمعاء (التهاب القولون الغشائي الكاذب) الذي قد يحدث بعد انتهاء العلاج بالمضادات الحيوية. أخبر طبيبك على الفور. فربما يكون من الضروري التوقف عن تناول الدواء وبدء علاج محدد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ عائلي من الإصابة باضطرابات إنزيمات الكبد أو لديك خلل في إنزيم الكبد المعروف باسم نازعة هيدروجين الجلوكوز-6-فوسفات (G6PD) (مرض وراثي نادر). قد يكون المرضى المصابون بنقص في نازعة هيدروجين الجلوكوز-6-فوسفات معرضين لخطر تكسر خلايا الدم الحمراء (تحلل خلايا الدم الحمراء) عند العلاج بالمواد المضادة للبكتيريا المُشتملة على مادة كينولون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني مشكلات في الكلية. قد يحتاج المرضى المصابون بانخفاض في نشاط الكلية (قصور كلوي) إلى جرعات أقل من المرضى ذوي النشاط الطبيعي في الكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي أدوية تسبب سيولة في الدم (وتُعرف باسم مضادات التجلط مثل الوارفارين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصبت من قبل بمشكلات صحية عقلية. أخبر طبيبك على الفور في حال ملاحظة تغير في رأيك أو أفكارك (تفاعل ذُهاني).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت من قبل بأعراض نتيجة تلف في الأعصاب مثل مشكلات في الحركة والإحساس في اليدين والقدمين، تزداد بشدة أثناء الليل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت من قبل بمشكلات في القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بداء السكري وتتناول أدوية عن طريق الفم لخفض مستويات الجلوكوز في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت من قبل بمشكلات في الكبد. يجب عليك التوقف عن العلاج والاتصال بطبيبك على الفور في حال تطور أعراض الإصابة بمرض كبدي مثل فقدان الشهية أو اصفرار الجلد أو بياض العين (اليرقان)، أو بول داكن اللون أو حكة أو اضطرابات في المعدة والأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تفاعلات حساسية لهذا الدواء. في تلك الحالة، يجب عليك التوقف عن العلاج على الفور والاتصال بطبيبك أو بطبيب الطوارئ.</p><p dir="RTL">مشكلات القلب</p><p dir="RTL">يجب توخي الحذر عند استخدام هذا النوع من الأدوية، إذا كنت مولوداً أو مصاباً بتاريخ عائلي من الإصابة بطول فترة الفاصل الزمنى QT &nbsp;(التي تظهر في مخطط كهربية القلب، لتسجيل معدل ضربات القلب)، أو عدم توازن نسبة الأملاح في الدم (وخاصة انخفاض مستوى البوتاسيوم أو الماغنيسيوم في الدم)، أو انخفاض معدل ضربات القلب أو ضعف في عضلة القلب (قصور في القلب)، أو تاريخ من الإصابة بأزمة قلبية (احتشار عضلة القلب)، أو كنتِ أنثى أو كنت كبيراً في السن أو تتناول أدوية أخرى ينتج عنها تغيرات غير طبيعية في مخطط كهربية القلب (انظر قسم &quot;التفاعلات مع الأدوية الأخرى&quot;)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصابك ضعف بالإبصار أو تأثرت عيناك باى مرض آخر، فاستشر أخصائي عيون على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التفاعلات مع الأدوية الأخرى </strong></p><p dir="RTL">يجب أن تخبر طبيبك إذا كنت تتناول أدوية أخرى من شأنها تغيير معدل ضربات قلبك: الأدوية التي تنتمي إلى مجموعة مضادات اضطرابات نظم ضربات القلب (مثل كينيدين، هيدروكينيدين، ديسوبيراميد، أميودارون، سوتاتول، دوفيتيليد، إيبوتيليد)، ومضادات الاكتئاب الثلاثية الحلقات، وبعض المواد المضادة للميكروبات (التي تنتمي إلى مجموعة الماكروليدات)، وبعض مضادات الذُهان.</p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى أو تناولتها مؤخراً. ويشمل ذلك الأدوية المتاحة دون وصفة طبية، بما في ذلك الأدوية المكونة من أعشاب.</p><p dir="RTL">قد تتداخل بعض الأدوية مع مفعول العلاج الخاص بك أو تغير مستويات تلك الأدوية التي تتناولها حالياً في الدم، لذا تأكد من مراجعة الطبيب أو الصيدلي قبل تناول أي أدوية أخرى سواء وصفها لك الطبيب أو قمت بشرائها دون وصفة طبية. أخبر طبيبك إذا كنت تتناول أياً من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أملاح الحديد (وتُستخدم لعلاج الأنيميا)، أو الأدوية المضادة للحموضة المشتملة على أملاح الماغنيسيوم أو الألومنيوم (أدوية علاج حرقة المعدة وألم المعدة) أو الأدوية المشتملة على هذه الاملاح. تعمل هذه العقاقير على تقليل امتصاص أقراص ليفوأكت وفاعليتها ومن ثم يحب تناولها قبل أو بعد تناول أقراص ليفوأكت بساعتين على الأقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوكرالفات (يُستخدم لحماية جدار المعدة). قد يؤثر في قابلية امتصاص أقراص ليفوأكت وبقلل من فاعليتها. يُفضل تناول سوكرالفات بعد أقراص ليفوأكت بساعتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات فيتامين ك مثل دواء وارفارين (يُستخدم لمنع تكون جلطات الدم). وقد يؤدي استخدامه في نفس الوقت مع أقراص ليفوأكت إلى زيادة في معدل النزيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثيوفيلين (يستعمل في علاج الربو). قد يزداد خطر الإصابة &quot;بتشنجات&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعمل دواء بروبينسيد (يُستخدم للوقاية من الإصابة بمرض النقرس) أو سيميتيدين (يُستخدم لعلاج القرح) على تقليل قدرة الكليتين على التخلص من مادة ليفوفلوكساسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (يُستخدم لعلاج الصدفية، التهاب الجلد، الروماتيزم). قد يستمر تأثير هذا الدوار لفترة طويلة في حال استخدامه في نفس الوقت مع أقراص ليفوأكت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات، وأحياناً تُعرف باسم الستيرويدات - تُستخدم لعلاج الالتهاب. قد تكون أكثر احتمالاً للإصابة بالتهاب و/أو كسر في أوتارك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيروئيدية (NSAIDs) - تُستخدم لعلاج الألم والالتهاب مثل الأسبرين وآيبوبروفين وفينبوفين، وكيتوبروفين وإندوميثاسين. قد تكون أكثر عرضة للإصابة بتشنج (نوبة صرع) عند تناولها مع أقراص ليفوأكت.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أقراص ليفوأكت مع الطعام والشراب </strong></p><p dir="RTL">يُمكن تناول أقراص ليفوأكت خلال الوجبات أو أي وقت آخر بين الوجبات. ابتلع الأقراص مع كوب من الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع </strong></p><p dir="RTL">لا تتناولي أقراص ليفوأكت إذا كنتِ حاملاً أو خلال فترة الرضاعة. فقد يتسبب ذلك في إلحاق الضرر بطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات </strong></p><p dir="RTL">قد تؤثر بعض الآثار الجانبية مثل الدوار والدوخة والاضطرابات البصرية في قدرتك على التركيز والتفاعل. تجنب القيادة أو تشغيل الآلات الخطيرة أو القيام بأنشطة مماثلة في حال الشعور باختلال قدرتك على التركيز والتفاعل.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً حسب وصف الطبيب.</p><p dir="RTL">يجب استشارة الطبيب أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">تعتمد مدة العلاج على نوع العدوى وشدتها.</p><p dir="RTL">سيخبرك طبيبك بعدد الأقراص التي يجب تناولها وأوقات الجرعات ومدة العلاج.</p><p dir="RTL">يحتاج أغلب الأشخاص إلى جرعة يومية مكونة من قرص أو قرصين. قد يحتاج المرضى ذوو القصور في نشاط الكُلية إلى جرعات أقل.</p><p dir="RTL"><strong>كيفية تناول هذا الدواء </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول هذا الدواء عن طريق الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الأقراص كاملة مع كوب من الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن تناول أقراص ليفوأكت خلال الوجبات أو أي وقت آخر بين الوجبات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>حماية البشرة من أشعة الشمس </strong></p><p dir="RTL">تجنب التعرض لأشعة الشمس المباشرة خلال فترة العلاج بهذا الدواء. وذلك لأن بشرتك ستُصبح أكثر حساسية للشمس وربما تُصاب بالحروق أو الوخز أو البثور المتقيحة إذا لم تتخذ الاحتياطات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من استخدام كريمات وقاية من الشمس ذات عامل حماية عالٍ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتدِ دائماً قبعة وملابس طويلة تغطي الذراعين والساقين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب الحمامات الشمسية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا كنت تتناول بالفعل أقراص حديد أو مضادات حموضة أو دواء سوكرالفات </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول هذا الدواء في نفس الوقت مع أقراص ليفوأكت المغلفة. تناول جرعتك من هذه الأدوية قبل أو بعد تناول أقراص ليفوأكت المغلفة بساعتين على الأقل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الكمية التي يجب تناولها </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقرر طبيبك عدد أقراص ليفوأكت المغلفة التي يجب عليك تناولها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستعتمد الجرعة على نوع العدوى والمكان المُصاب بالعدوى داخل جسمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستعتمد مدة العلاج على مدى خطورة العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال الشعور بأن تأثير الدواء ضعيف جداً أو قوي جداً، لا تغير الجرعة من تلقاء نفسك، ولكن استشر طبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>البالغون وكبار السن. </strong></p><p dir="RTL"><strong>عدوى الجيوب الأنفية </strong></p><p dir="RTL">قرص واحد من ليفوأكت 500 ملجم، مرة واحدة يومياً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>عدوى الرئتين، لدى الأشخاص الذين يعانون مشكلات طويلة الأمد في التنفس</strong>.</p><p dir="RTL">1/2 قرص أو قرص كامل من ليفوأكت 500 ملجم، مرة واحدة يومياً</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الالتهاب الرئوي </strong></p><p dir="RTL">قرص واحد من ليفوأكت 500 ملجم، مرة واحدة يومياً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>عدوى الجهاز البولي، ويشمل الكُليتين أو المثانة البولية</strong>.</p><p dir="RTL">1/2 قرص من ليفوأكت 500 ملجم، يومياً</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>عدوى غدة البروستاتا، حيث تكون مصاباً بعدوى لمدة طويلة </strong></p><p dir="RTL">قرص واحد من ليفوأكت 500 ملجم، مرة واحدة يومياً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>عدوى الجلد وما تحت الجلد، بما في ذلك العضلات </strong></p><p dir="RTL">1/2 قرص أو قرص كامل من ليفوأكت 500 ملجم، مرة واحدة أو مرتين يومياً</p><p dir="RTL">&nbsp;</p><p dir="RTL">البالغون المصابون بمشكلات في الكُلية</p><p dir="RTL">قد يحتاج طبيبك إلى إعطائك جرعة أقل</p><p>&nbsp;</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL"><strong>يجب ألا يُعطى هذا الدواء للأطفال والمراهقين</strong>.</p><p dir="RTL"><strong>ما يجب عليك القيام به عند تناول جرعة زائدة من أقراص ليفوأكت </strong></p><p dir="RTL">في حال تناول قرص واحد لعدة مرات عن طريق الخطأ، فمن غير المحتمل أن تُصاب بأي ضرر. في حال تناول العديد من الأقراص لعدة مرات عن طريق الخطأ، اتصل بطبيبك أو احصل على استشارة طبية أخرى. إن أمكن، اصطحب الأقراص أو العلبة معك لتُطلع الطبيب عليها. تتضمن علامات تناول جرعة زائدة بعض الأعراض مثل الارتباك والدوار واضطراب الوعي والإدراك ونوبات صرع (تشنجية) وخلل في وظيفة القلب، مما قد ينتج عنه عدم انتظام معدل ضربات القلب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حال نسيان تناول أقراص ليفوأكت </strong></p><p dir="RTL">في حال نسيان تناول إحدى الجرعات، تناولها بمجرد تذكر ذلك، إلا إذا اقترب موعد تناول الجرعة التالية. وبعدها تناول الجرعات في موعدها المحدد كما من قبل. لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن تناول أقراص ليفوأكت </strong></p><p dir="RTL">من المهم إنهاء مدة العلاج كاملة حسب وصف الطبيب. لا تتوقف عن تناول الدواء، حتى وإن بدأت تشعر بالتحسن قبل إنهاء مدة العلاج بالكامل. في حال التوقف عن تناول الأقراص بعد وقت قصير فربما تزداد حالتك سوءاً. في حال شعورك بالحاجة إلى وقف العلاج نتيجة لحدوث أحد الآثار الجانبية، أخبر طبيبك على الفور للحصول على استشارة قبل تناول الجرعة التالية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن طريقة استخدام هذا المنتج، فاسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء آثاراً جانبية، ولكنها لا تظهر بالضرورة على كل من يتناوله. ترد الآثار الجانبية في هذا القسم مع تقدير عدد المرات التي تحدث فيها. إذا تطور أي من هذه الآثار الجانبية لدرجة خطيرة، أو إذا لاحظت حدوث أي آثار جانبية غير مدرجة بهذه النشرة، فأخبر الطبيب</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>قد تحدث تفاعلات حساسية حادة بشكل نادر جداً. قد تحدث هذه الأعراض بعد الجرعة الأولى أو حتى بعد التوقف عن العلاج. <strong>في حال إصابتك بأي من هذه الآثار الجانبية خلال فترة العلاج بهذا الدواء، توقف عن تناول ليفوأكت على الفور وأخبر طبيبك أو توجه إلى قسم الإصابات التابع لأقرب مستشفى إليك</strong>. فيما يلي علامات حدوث تفاعلات الحساسية: </em></p><p dir="RTL">■&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة معدل ضربات القلب، انخفاض ضغط الدم، الحمى، مشكلات في التنفس، صدمة،</p><p dir="RTL">■&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه واللسان والحلق، تفاعلات الجلد مثل التورم والاحمرار، مشكلات في الدم، قرح في الفم والعينين والأمعاء والأعضاء التناسلية</p><p dir="RTL">■&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يظهر لدى بعض الأشخاص مشكلات خطيرة في الكبد. تتضمن علامات الإصابة بمشكلات في الكبد اصفرار الجلد والبول الداكن اللون وألم في المعدة وفقدان الشهية.</p><p dir="RTL">■&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وضعف في العضلات وشد عضلي دون سبب معروف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال مصحوب بنزول دم، حمى، وألم في المعدة بدرجة خفيفة إلى متوسطة (أعراض التهاب القولون الغشائي الكاذب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق في الأربطة (مثل: وتر العرقوب)، قد يحدث خلال 48 ساعة بعد بدء العلاج وقد يحدث وهن عضلي في الطرفين، مما يمثل أهمية خاصة لدى المرضى المصابين بمرض الوهن العضلي الوبيل (وهو مرض نادر يُصيب الجهاز العصبي)</p><p dir="RTL"><strong><em>قد يسبب دواء ليفوأكت نقصاً في عدد كرات الدم البيضاء مما يؤدي إلى إضعاف مقاومتك للعدوى. إذا كنت تعاني عدوى مصحوبة بأعراض مثل الحمى وتدهور تام في صحتك العامة أو حمى مصحوبة بأعراض عدوى موضعية مثل التهاب الحلق/المريء/الفم أو مشكلات في القناة البولية يجب عليك رؤية الطبيب على الفور. سيتم إجراء اختبار دم للتأكد من النقص المحتمل في عدد كرات الدم البيضاء (ندرة المحببات). من المهم إخبار طبيبك بشأن الدواء الذي تتناوله. </em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية الأخرى:</p><p dir="RTL"><u>آثاراً شائعة ( تؤثر في عدد يتراوح بين 1 و10 أشخاص من كل 100 شخص) </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستويات إنزيمات الكبد في الدم</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>آثاراً غير شائعة ( تؤثر في عدد يتراوح بين 1 و10 أشخاص من كل 1000 شخص) </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة والطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، أو اضطراباً في المعدة (عسر هضم)، أو قيء أو ألماً في منطقة البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداعاً، دوخة، دوار، اضطرابات في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو نقصاً في عدد كرات الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعفاً عاماً. قد يؤدي أي علاج مضاد للبكتيريا متخصص في قتل أنوع محددة من الجراثيم إلى حدوث خلل في الكائنات الحية الدقيقة (البكتيريا/ الفطريات) التي توجد داخل جسم الإنسان بشكل طبيعي. ومن ثم، قد يزداد عدد أنواع أخرى من البكتيريا أو الفطريات، الأمر الذي يستلزم العلاج في بعض الحالات النادرة</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>آثاراً نادرة ( تؤثر في عدد يتراوح بين 1 و10 أشخاص من كل 10,000 شخص) </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية العامة (التفاعلات التأقية/ تآقانية) (التي قد تحدث أحياناً بعد الجرعة الأولى وتتطور سريعاً خلال دقائق أو ساعات منذ تناول الدواء) وتكون مصحوبة بأعراض مثل الارتكاريا وتشنج في الشعب الهوائية ومشكلات حادة في التنفس، هذا بالإضافة إلى حالات نادرة جداً من تورم الجلد والأغشية المخاطية (في الوجه والحلق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوخز، في اليدين (المذل)، والارتعاش، و&quot;التشنجات&quot; (الاختلاجات) والارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق، الاكتئاب، التفاعلات الذُهانية، الأرق (الهياج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة غير طبيعية في سرعة ضربات القلب، انخفاضاً غير طبيعي في ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألماً والتهاباً في الأوتار أو ألماً في المفاصل أو ألماً في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقصاً في عدد الصفائح الدموية مما يؤدي إلى زيادة خطر الإصابة بكدمات وسهولة النزف</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>آثاراً نادرة الحدوث جداً (تؤثر فيما يقل عن شخص واحد من كل 10,000) </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاضاً مفاجئاً في ضغط الدم أو هبوطاً حاداً (صدمة)، وتفاعلات جلد معتدلة وزيادة في حساسية البشرة لأشعة الشمس والأشعة فوق البنفسجية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاضاً في مستوى السكر في الدم بشكل كبير جداً (نقص سكر الدم) مما يمثل أهمية خاصة لدى المرضى الخاضعين لعلاج داء السكري، ونوبات البورفيريا لدى المرضى المصابين بمرض البورفيريا (مرض شديد الندرة متعلق بعملية الأيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الرؤية والسمع، اضطرابات في حاسة التذوق والشم، شعوراً بالتخدير، اضطرابات في الحركة، وتشمل صعوبة في المشي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلوسة، وتفاعلات ذُهانية مع خطر التفكير في الانتحار أو حدوث محاولات للانتحار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وهط دوراني (صدمة تأقية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاضاً حاداً في عدد كرات الدم البيضاء (ندرة المحببات) مما يؤدي إلى حدوث بعض الأعراض مثل الإصابة بالحمى بشكل متكرر أو دائم، والتهاب الحلق والشعور بالإعياء مجدداً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد؛ اضطرابات في وظائف الكُلى وفشل كلوى مؤقت نتيجة تفاعلات الحساسية بالكلية (التهاب الكلية الخلالي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، أو الالتهاب التحسسي للأوعية الدموية الصغيرة أو تفاعلات الحساسية بالرئة.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>آثاراً غير محددة المعدل (لا يمكن تقدير معدل تكرارها من البيانات المتاحة). </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حادة تسبب طفحاً في الجلد والأغشية المخاطية (متلازمة ستيفنز جونسون)، وانحلال البشرة النخري السمي (متلازمة لايل) والحُمامَى العديدة الأشكال النضحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقصاً في عدد كرات الدم الحمراء (أنيميا) نتيجة تلف خلايا الدم، وزيادة في عدد جميع أنواع خلايا الدم الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مشكلات القلب</p><p dir="RTL">آثاراً جانبية غير معروفة: زيادة غير طبيعية في سرعة ضربات القلب وتبدل معدل ضربات القلب (المعروف &quot;بطول فترة QT في طب القلب&quot; وهي الفترة الزمنية بين بداية الموجة Q ونهاية الموجة T في مخطط كهربية القلب).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يُستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على العلبة. يشير تاريخ الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">يُحفظ الدواء في درجة حرارة لا تزيد على 30 ْم</p><p dir="RTL">يُحفظ الشريط في العلبة الكرتون الخارجية لحمايته من أشعة الشمس.</p><p dir="RTL">لا ينبغي التخلص من الأدوية عن طريق مياه الصرف أو النفايات المنزلية. سل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستعملها. تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي الليفوفلوكساسين.</p><p dir="RTL">يحتوي كل قرص من أقراص ليفوأكت 500 ملجم على 500 ملجم من هيميهيدرات الليفوفلوكساسين بما يعادل 500 ملجم من الليفوفلوكساسين.</p><p dir="RTL">أما المكونات الأخرى فهي:</p><p dir="RTL">&nbsp;محتوى القرص من الداخل: هيدروكسي بروبيل ميثيل السليولوز، وكروسبوفيدون، والسليلوز الدقيق البلورات، والسيليكا الغروانية اللامائية، نشا ذرة ما قبل التهلم وفومارات ستيريل الصوديوم.</p><p dir="RTL">مكونات الغلاف: غلاف أوبادري Y-1-7000 وأكسيد الحديد الأحمر (E-172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يأتي دواء ليفوأكت 500 ملجم في شكل أقراص مغلفة محدبة الوجهين باللون الوردي، ومقسومه من جانب واحد. يمكن تقسيم القرص إلى جرعتين متساويتين.</p><p dir="RTL">تحتوي كل علبة على&nbsp; عشرة أقراص (شريط واحد به عشرة أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مختبرات سينفا، ش.م.</p><p dir="RTL">شارع أولاز شيبي، 10 منطقة بوليغنو الصناعية</p><p dir="RTL">31620 أوارتي-بامبلونا (نافارا) - إسبانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أُجريت آخر مراجعة لهذه النشرة في مايو 2015 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levoact 500 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet of Levoact 500 mg contains 500 mg of levofloxacin as levofloxacin hemihydrate.
Excipients:
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Pink, coated tablet with a score line. The tablet can be divided in equal halves.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levoact tablets are indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1):<br />&bull; Acute bacterial sinusitis<br />&bull; Acute exacerbations of chronic bronchitis<br />&bull; Community-acquired pneumonia<br />&bull; Complicated skin and soft tissue infections.<br />For the above-mentioned infections Levoact should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.<br />&bull; Pyelonephritis and complicated urinary tract infections (see section 4.4)<br />&bull; Chronic bacterial prostatitis,<br />&bull; Uncomplicated cystitis (see section 4.4)<br />&bull; Inhalation Anthrax: post exposure prophylaxis and curative treatment (see section 4.4).<br />Levoact may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levoact tablets administered once or twice daily.<br />The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.<br />Levoact tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin; given the bioequivalence of<br />the parenteral and oral forms, the same dosage can be used.<br />Posology<br />The following dose recommendations can be given for Levoact:<br />Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min)<br />Indication<br />Daily dose regimen (according to severity)<br />Duration of the treatment (according to severity)<br />Acute bacterial sinusitis<br />500 mg once daily<br />10 &ndash; 14 days<br />Acute bacterial exacerbations of chronic bronchitis<br />500 mg once daily<br />7 &ndash; 10 days<br />Community-acquired pneumonia<br />500 mg once or twice daily<br />7 &ndash; 14 days<br />Pyelonephritis<br />500 mg once daily<br />7 &ndash; 10 days<br />Uncomplicated cystitis<br />250 mg once daily<br />3 days<br />Complicated urinary tract infections<br />500 mg once daily<br />7 &ndash; 14 days<br />Chronic bacterial prostatitis<br />500 mg once daily<br />28 days<br />Complicated skin and soft tissue infections<br />500 mg once or twice daily<br />7 &ndash; 14 days<br />Inhalation Anthrax<br />500 mg once daily<br />8 weeks<br />Special populations<br />Impaired renal function (creatinine clearance &le; 50 ml/min)<br />Creatinine clearance<br />Dose regimen<br />250 mg/24 h<br />500 mg/24 h<br />500 mg/12 h<br />first dose: 250 mg<br />first dose: 500 mg<br />first dose: 500 mg<br />50-20 ml/min<br />then: 125 mg/24 h<br />then: 250 mg/24 h<br />then: 250 mg/12 h<br />19-10 ml/min<br />then: 125 mg/48 h<br />then: 125 mg/24 h<br />then: 125 mg/12 h<br />&lt; 10 ml/min<br />(including haemodialysis and CAPD)1<br />then: 125 mg/48 h<br />then: 125 mg/24 h<br />then: 125 mg/24 h<br />1 No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD)<br />Impaired liver function<br />No adjustment of dosage is required since levofloxacin is not metabolized to any relevant extent by the liver and is mainly excreted by the kidneys.<br />Elderly population<br />No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function (see section<br />4.4 &ldquo;Tendinitis and tendon rupture&rdquo; and &ldquo;QT interval prolongation&rdquo;).<br />Paediatric population<br />Levofloxacin is contraindicated in children and growing adolescents (see section 4.3).<br />Method of administration<br />Levoact tablets should be swallowed without crushing and with sufficient amount of liquid. They may be divided at the score line to adapt the dose. The tablets may be taken during meals or between meals. Levoact tablets should be taken at least two hours before or after iron salts, zinc salts, magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents), and sucralfate administration, since reduction of absorption can occur (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levoact tablets must not be used:
• in patients hypersensitive to levofloxacin, or other quinolones or any of the excipients listed in section 6.1,
• in patients with epilepsy,
• in patients with history of tendon disorders related to fluoroquinolone administration,
• in children or growing adolescents,
• during pregnancy,
• in breast-feeding women
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methicillin-resistant S. aureus are very likely to possess co-resistance to fluroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).<br />Levofloxacin may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation of Chronic Bronchitis when these infections have been adequately diagnosed.<br />Resistance to fluoroquinolones of E. coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in E. coli to fluoroquinolones.<br />Inhalation Anthrax: Use in humans is based on in vitro Bacillus anthracis susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.<br />Tendinitis and tendon rupture<br />Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment.. The risk of tendinitis and tendon rupture is increased in patients aged over 60 years, in patients receiving daily doses of 1000 mg and in patients using corticosteroids. The daily dose should be adjusted in elderly patients based on creatinine clearance (see section 4.2). Close monitoring of<br />these patients is therefore necessary if they are prescribed levofloxacin. All patients should consult their physician if they experience symptoms of tendinitis. If tendinitis is suspected, treatment with levofloxacin must be halted immediately, and appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon (see section 4.3 and 4.8).<br />Clostridium difficile-associated disease<br />Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of Clostridium difficile-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis (see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation.<br />Patients predisposed to seizures<br />Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case<br />of convulsive seizures (see section 4.8), treatment with levofloxacin should be discontinued.<br />Patients with glucose-6-phosphate dehydrogenase deficiency<br />Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.<br />Patients with renal impairment<br />Since levofloxacin is excreted mainly by the kidneys, the dose of levofloxacin should be adjusted in patients with renal impairment (see section 4.2).<br />Hypersensitivity reactions<br />Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.<br />Severe bullous reactions<br />Cases of severe bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with levofloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.<br />Dysglycaemia<br />As with all quinolones, disturbances in blood glucose, including both hyperglycaemia and hypoglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g. glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).<br />Prevention of photosensitisation<br />Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or artificial UV rays (e.g. sunray lamp or solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.<br />Patients treated with vitamin K antagonists<br />Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).<br />Psychotic reactions<br />Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour, sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with a history of psychiatric disease.<br />QT interval prolongation<br />Caution should be taken when using fluroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:<br />- congenital long QT syndrome<br />- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics)<br />- uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)<br />- cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)<br />Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations (see sections 4.2 Elderly, 4.5, 4.8 and 4.9).<br />Peripheral neuropathy<br />Peripheral sensory neuropathy and peripheral sensory motor neuropathy have been reported in patients receiving fluroquinolones, including levofloxacin, which can be rapid in its onset (see section 4.8). Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.<br />Hepatobiliary disorders<br />Cases of hepatic necrosis up to life-threatening hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.<br />Exacerbation of myasthenia gravis<br />Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Post marketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.<br />Vision disorders<br />If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).<br />Superinfection<br />The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.<br />Interference with laboratory test<br />In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. It may be necessary to confirm positive opiate screens by more specific method.<br />Levofloxacin may inhibit the growth of Mycobacterium tuberculosis and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of other medicinal products on levofloxacin<br />Iron salts, zinc salts, magnesium- or aluminium-containing antacid, didanosines<br />Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminium- containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) are administered concomitantly with Levoact tablets. Concurrent administration of fluoroquinolones with multi-vitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) should not be taken 2 hours before or after Levoact tablet administration (see section 4.2). Calcium salts have a minimal effect on the oral absorption of levofloxacin.<br />Sucralfate<br />The bioavailability of levofloxacin is significantly reduced when administered together with sucralfate. If the patient is to receive both sucralfate and levofloxacin, it is best to administer sucralfate 2 hours after the levofloxacin administration (see section 4.2).<br />Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs<br />No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold. Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.<br />Probenecid and cimetidine<br />Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance. Caution should be exercised when levofloxacin is coadministered with drugs that aeffect the tubular renal secretion such as probenecid and cimetidine, especially in renal impaired patients.<br />Other relevant information<br />Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.<br />Effect of levofloxacin on other medicinal products Ciclosporin<br />The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.<br />Vitamin K antagonists<br />Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin).<br />Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4).<br />Drugs known to prolong QT interval<br />Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and I I antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4 QT interval prolongation).<br />Other relevant information<br />In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.<br />Other forms of interactions<br />Food<br />There is no clinically relevant interaction with food. Levoact tablets may therefore be administered<br />regardless of food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). However, in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women (see section 4.2 and 5.3).<br />Breast-feeding<br />The product is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk; however other fluoroquinolones are excreted in breast milk. In the absence of human data and due to the experimental data suggests risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women (see sections 4.3 and 5.3).<br />Fertility<br />Levofloxacin caused no impairment of fertility or reproductive performance in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient&#39;s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies in more than 8,300 patients and on extensive post marketing experience.<br />Frequencies are defined using the following convention: Very common (&ge;1/10)<br />Common ((&ge;1/100, &lt;1/10) Uncommon ((&ge;1/1,000, &lt;1/100) Rare (&ge;1/10,000, &le;1/1,000)<br />Very rare (&lt;1/10,000)<br />Not known (cannot be estimated from the available data).<br />Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.<br />System organ class<br />Common (&ge;1/100 to<br />&lt;1/10)<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Rare (&ge;1/10,000 to &lt; 1/1,000)<br />Not known (cannot be estimated from<br />Infections and infestations<br />Fungal infection including Candidia infection<br />Pathogen resistance<br />Blood and lymphatic system disorders<br />Leukopenia Eosinophilia<br />Thrombocytopenia Neutropenia<br />Pancytopenia Agranulocytosis Haemolytic anaemia<br />Immune system disorders<br />Angioedma<br />Hypersensitivity (see section 4.4)<br />Anaphylactic shocka<br />Anaphylactoid shocka (see section 4.4)<br />Metabolism and nutrition disorders<br />Anorexia<br />Hypoglycaemia particularly in diabetic patients (see section 4.4)<br />Hyperglycaemia<br />Hypoglycaemic coma (see section 4.4)<br />Psychiatric disorders<br />Insomnia<br />Anxiety Confusional state Nervousness<br />Psychotic reaction (with e.g. hallucinations, paranoia)<br />Depression Agitation Abnormal dreams Nightmares<br />Psychotic disorders with self-endangering behaviour including suicidal ideation or suicide attempt (see section 4.4)<br />Nervous system disorders<br />Headache Dizziness<br />Somnolence Tremor Dysgeusia<br />Convulsions (see section 4.3 and 4.4)<br />Parasethesia<br />Peripheral sensory neuropathy (see section 4.4)<br />Peripheral sensory motor neuropathy (see section 4.4)<br />Parosmia including anosmia<br />Dyskinesia<br />Extrapyramidal disorder<br />Ageusia Synocope<br />Benign intracranial hypertension<br />Eye disorders<br />Visual disturbances such as blurred vision (see section 4.4)<br />Transient vision loss (see section 4.4)<br />Ear and Labyrinth disorders<br />Vertigo<br />Tinnitus<br />Hearing loss Hearing impaired<br />Cardiac disorders<br />Tachycardia Palpitation<br />Ventricular tachycardia, which may result in cardiac arrest<br />Venticular arrhythmia and torsade de pointes (reported predominantly in patients with risk factors of QT prolongation), electrocardiogram QT prolonged (see sections 4.4 and 4.9)<br />Vascular disorders<br />Applies to i.v. form<br />Hypotension<br />only: Phlebitis<br />Respiratory, thoracic and medistinal disorders<br />Dyspnoea<br />Bronchospasm Pneumonitis<br />Gastro-intestinal disorders<br />Diarrhoea Vomiting Nausea<br />Abdominal pain Dyspepsia Flatulence Constipation<br />Diarrhoea &ndash; haemorrhagic which in very rare cases may be indicative of enterocolitis, including pseudomembranous colitis (see section 4.4)<br />Pancreatitis<br />Hepatobiliary disorders<br />Hepatic enzyme increased (ALT/AST, alkaline phosphatase, CGT)<br />Blood bilirubin increased<br />Jaundice and severe liver injury, including cases with fatal acute liver failure, primarily with severe underlying diseases (see section 4.4)<br />Skin and subcutaneous tissue disordersb<br />Rash Pruritus Urticaria<br />Hyperhidrosis<br />Toxic epidermal necrolysis<br />Stevens-Johnson syndrome<br />Erythema multiforme<br />Photosensitivity reaction (see section 4.4)<br />Leukocytoclastic vasculitis<br />Musculoskeletal and connective tissue disorders<br />Arthralgia Myalgia<br />Tendon disorders (see sections 4.3 and 4.4) including tendinitis (e.g. Achilles tendon)<br />Muscle weakness which may be of special importance in patients with myasthenia gravis (see section 4.4)<br />Rhabdomyolysis<br />Tendon rupture (e.g. Achilles tendon) (see sections 4.3 and 4.4)<br />Ligament rupture Muscle rupture Arthritis<br />Renal and Urinary disorders<br />Blood creatinine increased<br />Renal failure acute (e.g. due to interstitial<br />General disorders and administration site conditions<br />Applies to i.v. form only:<br />Infusion site reaction (pain, reddening)<br />Asthenia<br />Pyrexia<br />Pain (including pain in back, chest, and extremities)<br />aAnaphylactic and anaphylactoid reactions may sometimes occur even after the first dose<br />bMucocutaneous reactions may sometimes occur even after the first dose<br />Other undesirable effects which have been associated with fluoroquinolones administration include:<br />&bull; attacks of porphyria in patients with porphyria.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.<br />To report any side effect(s):<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone: 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdose of levofloxacin tablets are central nervous symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.<br />CNS effects include confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.<br />In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Antacids may be used for protection of gastric mucosa.<br />Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body. No specific antidote exists.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Quinolone antibacterials - Fluoroquinolones<br />ATC code: J01MA12<br />Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S(-) enatiomer of the racemic drug substance ofloxacin.<br />Mechanism of action<br />As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.<br />PK/PD relationship<br />The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).<br />Mechanism of resistance<br />Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type I topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to levofloxacin.<br />Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.<br />Breakpoints<br />The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/L).<br />EUCAST clinical MIC breakpoints for levofloxacin (version 2.0, 2012-01-01)<br />Pathogen<br />Susceptible<br />Resistant<br />Entecobacteriaceae<br />&le; 1 mg/L<br />&gt;2 mg/L<br />Pseudomonas spp.<br />&le; 1 mg/L<br />&gt;2 mg/L<br />Acinetobacter spp.<br />&le; 1 mg/L<br />&gt;2 mg/L<br />Staphylococcus spp.<br />&le; 1 mg/L<br />&gt;2 mg/L<br />S. pneumoniae1<br />&le; 2mg/L<br />&gt; 2 mg/L<br />Streptococcus A, B, C ,G<br />&le; 1 mg/L<br />&gt;2 mg/L<br />H. influenzae2,3<br />&lt;1 mg/L<br />&gt;1 mg/L<br />M. catarrhalis3<br />&lt;1 mg/L<br />&gt;1 mg/L<br />Non-species related breakponts4<br />&le; 1 mg/L<br />&gt;2 mg/L<br />1The breakpoints for levofloxacin relate to high dose therapy.<br />2Low-level fluoroquinolone resistance (ciprofloxacin MICs of 0.12 -05 mg/l) may occur but there is no evidence that this resistance is of clinical importance in respiratory tract infections with H. influenza.<br />3Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant.<br />4Breakpoints apply to an oral dose of 500 mg x 1 to 500 mg x 2 and an intravenous dose of 500 mg x 1 to 500 mg x 2..<br />The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.<br />COMMONLY SUSCEPTIBLE MICROORGANISMS<br />Aerobic Gram-positive bacteria Bacillus anthracis<br />Staphylococcus aureus* methicillin susceptible Staphylococcus saprophyticus<br />Stretococci, groups C and G Streptococcus agalactiae Streptococcus pneumoniae* Streptococcus pyogenes*<br />Aerobic Gram-negative bacteria Eikenella corrodens<br />Haemophilus influenzea Haemophilus para-influenzae Klebsiella oxytoca<br />Moraxella catarrhalis Pasteurella multocida Proteus vulgaris Providencia rettgeri Anaerobic bacteria Peptostreptococcus Other<br />Chlamydophila pneumoniae Chlamydophila psittaci Chlamydia trachomatis Legionella pneumophila Mycoplasma pneumoniae Mycoplasma hominis Ureaplasma urealyticum<br />SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM<br />Aerobic Gram-positive bacteria<br />Enterococcus faecalis<br />Staphylococcus aureus methicillin-resistant# Coagulase negative Staphylococcus spp<br />Aerobic Gram-negative bacteria Acinetobacter baumanni<br />Citrobacter freundi Enterobacter aerogenes Enterobacter cloacae Escherichia coli<br />Klebsiella pheumoniae Morganella morganii Proteus mirablis Providencia stuartii Pseudomonas aeruginosa Serratia marcescens Anaerobic bacteria Bacteroides fragilis<br />INHERENTLY RESISTANT STRAINS<br />Aerobic Gram-positive bacteria Enterococcus faecium<br />#Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1 &ndash; 2 h. The absolute bioavailability is 99 - 100%.<br />Food has little effect on the absorption of levofloxacin.<br />Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.<br />Distribution<br />Approximately 30 &ndash; 40% of levofloxacin is bound to serum protein. The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated doses, indicating widespread distribution into body tissues.<br />Penetration into tissues and body fluids:<br />Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration intro cerebro-spinal fluid.<br />Biotransformation<br />Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for &lt; 5% of the dose excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.<br />Elimination<br />Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t&frac12;: 6 &ndash; 8 h). Excretion is primarily by the renal route (&gt;85% of the administered dose).<br />The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/- 29.2 ml/min.<br />There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.<br />Linearity<br />Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.<br />Special populations<br />Subjects with renal insufficiency<br />The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:<br />Pharmacokinetics in renal insufficiency following single oral 500 mg dose<br />Clcr [ml/min]<br />&lt;20<br />20 &ndash; 49<br />50 &ndash; 80<br />ClR [ml/min]<br />13<br />26<br />57<br />t&frac12; [h]<br />35<br />27<br />9<br />Elderly subjects<br />There are no significant differences in levofloxacin kinetics between young and elderly subjects, except those associated with differences in creatinine clearance.<br />Gender differences<br />Separate analysis for male and female subjects showed a small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.<br />Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on foetuses was delayed maturation as a result of maternal toxicity.<br />Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster cells in vitro. These effects can be attributed to inhibition of topoisomerase II. In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.<br />Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenicity study.<br />In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:<br />Hydroxypropylmethylcellulose<br />Crospovidone<br />Microcrystalline cellulose<br />Colloidal anhydrous silica<br />Pregelatinized corn starch<br />Sodium stearyl fumarate<br />Film coating<br />Opadry Y-1-7000<br />Red iron oxide (E -172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store at a temperature above 30&ordm;C</p><p>Keep the blister in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White PVC-PVDC-aluminium blisters with film-coated tablets.<br />The 500 mg tablets are available in 10-tablet packs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABORATORIOS CINFA, S.A.
Olaz-Chipi, 10 – Polígono Areta
31620 Huarte-Pamplona (Navarra), Spain.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 July 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>